Clinical Research Directory
Browse clinical research sites, groups, and studies.
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
Sponsor: University Hospital, Ghent
Summary
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.
Official title: Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Brodalumab and the Development of Concentration-response Curve of Brodalumab of Psoriasis Patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2018-12-14
Completion Date
2024-12-31
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
Patient questionnaires
The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
Locations (7)
AZ Maria Middelares
Ghent, Oost-Vlaanderen, Belgium
AZ Sint-Lucas
Ghent, Oost-Vlaanderen, Belgium
University Hospital of Ghent
Ghent, Oost-Vlaanderen, Belgium
Private Practice Dermatology
Maldegem, Oost-Vlaanderen, Belgium
University Hospital
Leuven, Vlaams-Brabant, Belgium
AZ Sint-Jan
Bruges, West-Vlaanderen, Belgium
AZ Delta Rembert
Torhout, West-Vlaanderen, Belgium